Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Liberté stent performance update

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific's Taxus Liberté paclitaxel-eluting stent demonstrates 3.7% cardiac event rate at 12 months in phase one of the firm's Olympia trial (529 patients), and a 3% cardiac event rate at six months in phase three (2,066 patients). The registry-based study, for which preliminary results were released Oct. 25 at TCT, will include up to 27,000 patients and is designed to reflect evolving "real world" usage patterns, including use in diabetics, multi-vessel disease, small vessels and complex lesions, says investigator Martyn Thomas, MD, King's College Hospital, London. Separately, the 871-patient Atlas Workhorse trial demonstrates noninferiority of Liberté to the Taxus Express paclitaxel-eluting stent, based on nine-month target vessel revascularization (TVR) rates of 8% and 7.1%, respectively, and equally low cardiac event and stent thrombosis rates, Boston Scientific says. Nine-month data from the 247-patient Direct trial with Liberté show that direct stenting without balloon predilation of the vessel is safe and effective when compared with predilation. Direct stenting has a 97.6% delivery success rate and "less target lesion revascularization, TVR and major adverse cardiac events," according to investigator John Ormiston, MD, Auckland City Hospital, New Zealand. In May, the firm gained expanded CE mark indications for Liberté, making it the only drug-eluting stent cleared for treating restenotic lesions and total occlusions in patients with coronary artery disease 1("The Gray Sheet" May 22, 2006, p. 14). The company expects to launch Liberté in the U.S. in 2007...

You may also be interested in...



Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.

AZ Will Sideline ‘Lucky Mistake’ Data To Secure COVID-19 Vaccine Approval

A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel